Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oral cancer test gets UK boost:

This article was originally published in Clinica

Executive Summary

Zila's UK licensee Stafford-Miller, a division of Block Drug, is launching a marketing campaign for Zila's OraTest oral cancer detection system. The five-minute mouth-rinse for squamous cell carcinoma is known as OraScreen in the UK. Stafford-Miller is aiming the campaign at dentists in general practice. The product is available or approved in Australia, Canada, Taiwan, Hungary, Bermuda and other countries. FDA approval is pending.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT080967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel